XML 79 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Financing (Tables)
 9 Months Ended
Sep. 29, 2023
Debt Disclosure [Abstract]  
Components of Debt The components of the Company’s debt were as follows ($ in millions):
Outstanding Amount
Description and Aggregate Principal AmountSeptember 29, 2023December 31, 2022
Euro-denominated commercial paper (€1.9 billion)(e)
$1,982 $2,013 
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”)(c)
590 584 
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)(f)
951 962 
2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma Notes”)(b)
699 698 
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(f)
499 499 
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(b)
1,317 1,333 
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(f)
844 854 
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d)
206 234 
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(a)
632 639 
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(b)
1,315 1,331 
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)(c)
232 230 
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”)(b)
796 796 
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(f)
846 856 
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)(b)
1,841 1,863 
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(d)
355 404 
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)(b)
1,307 1,323 
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”)(b)
891 890 
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(f)
499 499 
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)(b)
784 794 
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”)(b)
890 889 
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(f)
981 981 
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(f)
984 984 
Other15 21 
Subtotal$19,456 $19,677 
Veralto debt:
5.50% senior unsecured bonds due 9/18/2026 ($700 million) (the “2026 Veralto Bonds”)(g)
695 — 
5.35% senior unsecured bonds due 9/18/2028 ($700 million) (the “2028 Veralto Bonds”)(g)
694 — 
4.15% senior unsecured bonds due 9/19/2031 (€500 million) (the “2031 Veralto Bonds”)(g)
523 — 
5.45% senior unsecured bonds due 9/18/2033 ($700 million) (the “2033 Veralto Bonds”)(g)
692 — 
Total Veralto debt$2,604 $— 
Total debt22,060 19,677 
Less: currently payable(2,547)(591)
Long-term debt$19,513 $19,086 
(a) Issued by DH Europe Finance S.A. (“Danaher International”).
(b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”).
(c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”).
(d) Issued by DH Japan Finance S.A. (“Danaher Japan”).
(e) Issued by Danaher Corporation or Danaher International II.
(f) Issued by Danaher Corporation.
(g) Issued by Veralto Corporation.